How to Get Prior Authorization for Wegovy or Zepbound

Getting prior authorization for Wegovy or Zepbound is one of the most frustrating parts of the GLP-1 journey. Your doctor has recommended it. You've looked up the research. And now you're stuck waiting on an insurance bureaucracy to decide whether you qualify. This guide walks through exactly what insurers want, how the process works at five major insurers, how long a decision legally can take in 2026, and what to do if they say no. Both medications require a prescription, so everything here happens in partnership with a licensed prescriber.

Last verified: 2026-07-10 by RxPickr Editorial Team. Insurer policy criteria, federal timing rules, and appeal statistics below were verified against primary sources on the date shown. Read our methodology for how we evaluate and re-verify data.

For the broader picture on whether your plan covers GLP-1s at all, see our GLP-1 insurance coverage guide. This article focuses on the prior auth process specifically: once you know your plan may cover it, here's how to move forward.

What Is Prior Authorization?

Prior authorization (sometimes called PA, pre-authorization, or pre-approval) is a requirement that your insurer approve a medication before your pharmacy will fill it at the covered price. The insurer reviews your medical history and confirms you meet their coverage criteria; only then does the medication become billable to your benefits.

It exists because insurers want evidence that a treatment is medically necessary for your specific situation, not just that it's FDA-approved in general. For GLP-1 medications, which can cost well over $1,000 per month at retail pharmacy prices without coverage as of July 2026 (prices vary by pharmacy and dose; wegovy.com), insurers almost universally require it.

Why Wegovy and Zepbound Almost Always Require It

Both Wegovy (semaglutide) and Zepbound (tirzepatide) are branded, high-cost medications. Insurers use prior authorization to control utilization, and for GLP-1s specifically, to verify that the patient meets clinical thresholds before approving coverage.

The FDA approved Wegovy for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol (DailyMed, Wegovy prescribing information). Zepbound received similar indications (DailyMed, Zepbound prescribing information). Insurers generally mirror these FDA criteria, but many add their own requirements on top.

Even plans that technically cover GLP-1s for weight management may require PA on every refill cycle, not just the initial fill. Some also require step therapy, meaning you may need to show you tried a different treatment first.

What Your Insurer Needs to Approve It

Every plan is different, but most prior authorization requests for Wegovy or Zepbound require some combination of the following:

Clinical documentation your prescriber will gather:

• Your current BMI, recorded in a recent office visit note
• Diagnosis of at least one weight-related comorbidity if your BMI is below 30 (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea are the most commonly accepted)
• Documentation that you have been counseled on diet and lifestyle modification
• Lab work, especially if a comorbidity like diabetes or high cholesterol is part of the clinical rationale

Plan-specific requirements that vary:

• Proof of a prior weight management attempt (some plans require 3–6 months of documented diet or exercise program participation)
• Step therapy, meaning evidence you tried a lower-cost intervention or an older weight-loss medication first
• Confirmation that the prescribing provider is in-network or authorized to prescribe obesity medications
• An active membership in a structured weight management program (some plans require this to be ongoing)

The best source for your plan's exact criteria is the drug's coverage policy document, which your insurer must provide on request. Search your insurer's website for "prior authorization criteria" plus the drug name, or ask your prescriber's office; they often have the list on file.

How Five Major Insurers Handle Wegovy and Zepbound PA

We pulled the current published policy documents for five major insurers. Two caveats before the table. First, these are the insurers' standard policy templates: self-funded employers customize benefits, and an employer that excludes weight-loss drugs entirely overrides everything below. Second, "Blue Cross Blue Shield" is a family of more than 30 independent companies, so we cite the Federal Employee Program policy as the most broadly applicable published example.

Insurer	Policy document	Lifestyle requirement	Initial authorization	Renewal
UnitedHealthcare	Program 2026 P 1114-21, effective 7/1/2026	Adjunct to lifestyle modification	Wegovy: 5 months. Zepbound: 6 months	12 months
Cigna	Policy IP0206, effective 6/1/2026	3-month behavioral modification and diet trial before starting	8 months	12 months
Aetna	Policy 4774-C, v2 (2023; most recent published version)	6 months in a comprehensive weight management program before drug therapy	7 months	12 months, requires 5% weight loss
BCBS Federal Employee Program	Policy 5.99.027, effective 1/1/2026	Participation in a comprehensive weight management program	6 months	Requires 5% BMI reduction
Kaiser Permanente NW	Zepbound criteria, revised 6/11/2026, effective 6/18/2026	Active lifestyle modification or behavioral health referral	12 months (clinical review; Zepbound is non-formulary)	Clinical review

UnitedHealthcare runs weight-loss coverage as an optional employer program. Its published criteria require that the medication be "used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)" plus either obesity-range BMI or overweight-range BMI with a weight-related comorbidity. Initial authorization is 5 months for Wegovy and 6 months for Zepbound; reauthorization runs 12 months and requires documented clinical response plus continued lifestyle modification (UnitedHealthcare Pharmacy PA program 2026 P 1114-21, effective July 1, 2026).

Cigna requires that the patient "has engaged in a trial of behavioral modification and dietary restriction for at least 3 months" before initial approval, and it recognizes an unusually long comorbidity list for the overweight pathway, including knee osteoarthritis, asthma, COPD, metabolic dysfunction-associated steatotic liver disease, and PCOS alongside the usual hypertension, type 2 diabetes, dyslipidemia, and sleep apnea. Initial approval for Wegovy or Zepbound is 8 months, with 1-year renewals (Cigna coverage policy IP0206, effective June 1, 2026). The same policy notes that many Cigna benefit plans exclude weight-loss drugs entirely, so the criteria only matter if your plan includes the benefit.

Aetna has the longest lifestyle prerequisite of the group: participation in "a comprehensive weight management program that encourages behavioral modification, reduced calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy." Initial approval is 7 months, and continuation requires documented loss of "at least 5 percent of baseline body weight" or maintenance of that loss (Aetna pharmacy clinical policy bulletin 4774-C). Note that Aetna's bulletin is the oldest document in this table (the published version predates 2026), so confirm your plan's current criteria before relying on it.

BCBS Federal Employee Program covers Wegovy and Zepbound for adults with a BMI of 30 or higher, or 27 or higher with established cardiovascular disease or a weight-related comorbidity, plus participation in a comprehensive weight management program (the policy names Teladoc as an example). Authorizations run in 6-month blocks, dual therapy with a second PA weight-loss drug is not covered, and the renewal standard requires a 5% BMI reduction (FEP pharmacy policy 5.99.027, effective January 1, 2026).

Kaiser Permanente varies by region and runs GLP-1 requests through internal clinical review. The Northwest region's current Zepbound criteria treat the drug as non-formulary and approve 12 months of coverage when the member's plan includes a weight-loss drug benefit, BMI has been documented within the last 30 days, BMI is 30 or higher (or 27 or higher with a documented comorbidity), and the patient is "actively making lifestyle modification (diet and/or exercise)" or has an active behavioral health referral (Kaiser Permanente NW commercial criteria, revised June 11, 2026). Notably, KFF found Kaiser Foundation Health Plan had the lowest appeal overturn rate among major Medicare Advantage insurers at 51.0% (KFF, 2024 data), so getting the initial Kaiser submission right matters more than average.

Step-by-Step: How to Start the PA Process

1. Confirm your plan actually covers the drug. Call the member services number on the back of your insurance card and ask: "Does my plan cover Wegovy or Zepbound for weight management, and is prior authorization required?" Get the answer in writing if you can; ask them to send a summary to your member portal. You can also check your plan's formulary online. Our article does insurance cover Wegovy or Zepbound? walks through how to read a formulary.

2. Talk to your prescriber before they submit anything. Your prescriber's office initiates the PA request, but the strength of that request depends on what documentation they include. Ask your provider: "Can you document my BMI, the comorbidities I have, and any prior weight management attempts in your notes?" A thorough clinical note strengthens the request: reviewers evaluate criteria from what's documented in the submission. Bring the submission checklist below to that visit.

3. Your prescriber submits the request. The PA form goes from your provider's office (or the telehealth platform's care team) directly to your insurer or pharmacy benefit manager. You generally don't submit this yourself. At this stage, the request enters a review queue. Ask for the confirmation or reference number.

4. The insurer reviews and decides. The insurer's medical reviewers evaluate whether your documented history meets their criteria. They may approve it, deny it, or request additional information (including peer-to-peer review, where the reviewing doctor speaks directly with your prescriber).

5. You receive a determination. Approvals come with an authorization number valid for a defined period, typically 5–8 months initially and 12 months on renewal at the insurers above. If denied, you receive a denial letter, and that letter triggers your appeal rights, covered below.

Timeline: How Long Does Prior Auth Take?

As of 2026, there are two sets of federal deadlines worth knowing, plus the practical reality.

If you're on Medicare Advantage, Medicaid, CHIP, or a federal Marketplace plan: the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), which took effect January 1, 2026, requires impacted payers to decide expedited prior authorization requests within 72 hours and standard requests within 7 calendar days, and to give a specific reason for any denial (CMS, 2024). Impacted payers include Medicare Advantage organizations, Medicaid and CHIP fee-for-service and managed care plans, and Qualified Health Plan issuers on the Federally Facilitated Exchanges, per the same CMS rule. The rule's electronic prior authorization API requirements phase in by January 1, 2027, so expect the process to keep getting faster. The clock starts when the insurer has a complete packet, which is why the checklist below matters. Our letter of medical necessity guide covers how to use these deadlines to your advantage.

If you're on an employer-sponsored plan: federal ERISA claims regulations require pre-service claims (which is what a PA request is) to be decided within a reasonable period, but not later than 15 days after receipt, with one 15-day extension permitted; urgent care claims must be decided within 72 hours (29 CFR 2560.503-1). Routine weight management requests rarely qualify as urgent.

In practice: expect one to three weeks. PlushCare, which handles prior auth on behalf of its patients, notes that the process typically takes 7–14 business days (PlushCare, April 2026). Ro's insurance concierge team estimates a similar window of 1–3 weeks to coordinate coverage (Ro, April 2026).

A few things can extend the timeline:

• The insurer requests additional clinical records from your provider
• Your provider's office is slow to respond to requests for more information
• The insurer triggers a peer-to-peer review, which requires scheduling between two physicians

If you haven't heard anything by day 8 (regulated plans) or day 15 (employer plans), call your insurer, ask for the status by the reference number your provider gave you, and follow up with your prescriber's office to confirm they've responded to any outstanding requests. A late decision is itself grounds for escalation.

The PA Submission Checklist

Many denials stem from documentation gaps rather than hard ineligibility. Copy this checklist, print it, and check off every line before your prescriber submits. Anything you can't check is the thing your denial letter will cite.

WEGOVY / ZEPBOUND PRIOR AUTHORIZATION CHECKLIST

PLAN INTELLIGENCE
[ ] Formulary status confirmed: is Wegovy or Zepbound the plan's
    preferred GLP-1? (Requesting the non-preferred drug is a
    common avoidable denial.)
[ ] Your plan's PA criteria document downloaded or requested
    (search "[insurer] Wegovy prior authorization criteria")
[ ] Member ID, group number, and pharmacy benefit manager name
    (e.g., OptumRx, Express Scripts, CVS Caremark) written down
[ ] Plan-specific PA form pulled by prescriber's office (generic
    forms get bounced by some PBMs)

CLINICAL RECORD
[ ] Current BMI documented at an office visit within the last
    30-90 days, with height and weight in the note
[ ] At least one historical BMI from 6-12 months ago
[ ] ICD-10 codes on the request: E66.01 or E66.9 (obesity) or
    E66.3 (overweight), PAIRED with the matching Z68 BMI code
[ ] Every qualifying comorbidity coded and evidenced:
    - E11.9 type 2 diabetes (recent A1c value)
    - I10 hypertension (recent BP readings)
    - E78.5 hyperlipidemia (recent lipid panel)
    - G47.33 obstructive sleep apnea (sleep study report)
[ ] Contraindication screening in the note (no personal/family
    history of medullary thyroid carcinoma or MEN 2)

PRIOR ATTEMPTS AND STEP THERAPY
[ ] Weight management program participation documented WITH
    DATES (3 months for Cigna, 6 months for Aetna-style plans)
[ ] Prior weight-loss medications listed with dates, doses, and
    outcomes (phentermine, naltrexone-bupropion, orlistat)
[ ] Dietitian referrals or behavioral counseling visits with dates

SUBMISSION PACKAGE
[ ] Letter of medical necessity attached (see our LMN template)
[ ] Prescriber NPI, practice phone, and fax on every page
[ ] Requested drug, exact dose, and titration schedule stated
[ ] Confirmation/reference number recorded after submission
[ ] Calendar reminder set: follow up day 8 (CMS-regulated plans)
    or day 15 (employer plans)

The ICD-10 pairing convention commonly trips up submissions: coding guidance expects an E66 obesity code to be accompanied by the matching Z68 BMI code (CMS, ICD-10-CM), and a missing Z68 code can read to a reviewer as missing BMI documentation. For the letter of medical necessity line, our LMN guide with a copy-ready template pairs directly with this checklist.

What to Do If You're Denied

A denial is not the end, and the numbers back that up. In Medicare Advantage, 80.7% of appealed prior authorization denials were partially or fully overturned in 2024, and more than eight in ten appealed denials were overturned every year from 2019 through 2024. Yet only 11.5% of denied requests were appealed at all (KFF). In ACA Marketplace plans, fewer than 1% of denied claims were appealed in 2024, and insurers upheld 66% of the internal appeals that were filed, meaning roughly one in three succeeded (KFF). Those figures cover all claim types, not GLP-1s specifically, but the pattern is clear: most denials were never appealed, and the appeals that were filed frequently succeeded.

Step 1: Read the denial letter carefully. The letter must specify the reason for denial, and under CMS-0057-F, impacted payers are now required to provide a specific reason (CMS, 2024). This is the foundation of your appeal. Common reasons include: not meeting BMI criteria, insufficient documentation of comorbidities, missing prior treatment history, or the drug not being on the plan's formulary.

Step 2: File an internal appeal. Under the Affordable Care Act, most private insurance plans are required to offer an internal appeal process (Healthcare.gov). You generally have 180 days from the denial to file. Submit a written appeal with a letter of medical necessity from your prescriber: a detailed clinical argument for why the medication is appropriate for your specific case, addressing the exact gap the denial letter cited.

Step 3: Request a peer-to-peer review. Your prescriber can call the insurer's medical reviewer directly and make the clinical case, addressing the reviewer's specific objection in real time. Ask your provider's office if they're willing to do this; many telehealth platforms will arrange it on your behalf.

Step 4: File an external appeal. If the internal appeal is denied, you have the right to an independent external review in most states (HealthCare.gov, External Review). An external reviewer not employed by your insurer evaluates whether the denial was appropriate, and the decision is binding on the plan. External appeals are especially useful when the insurer's decision contradicts established clinical guidelines. Our full appeals playbook walks through each level with scripts and deadlines.

Step 5: Explore alternatives while you wait. If you need medication now and the appeal process is stretching on, see our guide on GLP-1 options without insurance. Compounded GLP-1 options through cash-pay telehealth platforms can bridge the gap, though it's worth noting that compounded semaglutide and tirzepatide are not FDA-approved as finished products and differ from Wegovy and Zepbound.

The 2026 Coverage Landscape: What Changed

Prior authorization strategy in 2026 is shaped as much by formulary politics as by clinical criteria. Four shifts worth knowing:

CVS Caremark made Wegovy the preferred GLP-1. Effective July 1, 2025, CVS Caremark removed Zepbound from its standard template commercial formularies and made Wegovy the preferred obesity medication; existing Zepbound authorizations were transitioned to Wegovy (Mass.gov announcement). Zepbound is scheduled to return to CVS Caremark's commercial formularies as an additional preferred option on October 1, 2026, per trade press reports (as reported by Managed Healthcare Executive). If your PBM is Caremark, requesting Wegovy first (or waiting for the October change) may avoid an automatic non-formulary denial.

Some Blues plans exited weight-loss GLP-1 coverage entirely. Blue Cross Blue Shield of Massachusetts stopped covering GLP-1s prescribed for weight loss on standard plans as of January 1, 2026, while continuing diabetes coverage; large employers can buy the coverage back as a rider (Blue Cross Blue Shield of Massachusetts provider fact sheet). No PA strategy overrides a benefit exclusion, so confirm the benefit exists before investing effort in a submission.

Coverage churn is real. Research from GoodRx found that from 2025 to 2026, about 12 million people were on plans that dropped Zepbound coverage and 12 million were on plans that dropped Wegovy, as reported by KFF Health News (June 2026). If you got approved last year, re-verify your formulary at renewal rather than assuming the authorization carries over.

Employer coverage is holding but under pressure. In 2024, 44% of employers with 500 or more employees covered weight-loss medications (64% among those with 20,000 or more), and 77% of large employers now say managing GLP-1 costs is extremely or very important (Mercer, Survey on Health & Benefits Strategies for 2026). A Business Group on Health survey fielded in early 2026 found 67% of large employers covered GLP-1s for weight management, but only 72% of those said they were likely to maintain that coverage in 2027, as reported by Yahoo Finance (June 2026). The practical takeaway: if your plan covers these drugs today, submitting a complete PA now beats waiting.

Providers That Handle Prior Auth For You

One of the most practical ways to improve your odds is to use a telehealth platform whose care team manages the prior auth process end to end. These providers have staff experienced in submitting PA requests, responding to insurer requests for information, and advocating through appeals.

Ro has a dedicated insurance concierge team that verifies your benefits, submits the PA request, and communicates with your insurer directly. The service is available for commercial insurance plans. Learn more about Ro.

PlushCare is built around an insurance-first model. Board-certified physicians document your case specifically for PA submission, and the care team manages the authorization process through approval. PlushCare accepts most major insurance plans. Learn more about PlushCare.

Found offers a free insurance check before you commit, and their team manages the PA process for patients using insurance. Found offers a broad medication range, which also gives them flexibility to request alternative drugs if a first choice is denied. Learn more about Found.

Mochi Health integrates with major insurance plans and includes prior auth support as part of its clinical program. Learn more about Mochi Health.

Tips to Improve Your Approval Odds

Get your BMI documented before anything else. Denial letters frequently cite insufficient clinical documentation rather than hard ineligibility. If your prescriber's visit note doesn't explicitly state your BMI and link it to the clinical indication, the reviewer may deny it on a technicality. Kaiser Permanente NW's criteria even require BMI documented within the last 30 days, so recency matters.

List every qualifying comorbidity, with codes. If your BMI is 28 and you have hypertension, that comorbidity is your approval pathway. Make sure it's in the clinical note with the ICD-10 code and supporting evidence (a blood pressure reading, an A1c, a sleep study); reviewers work from what's in the submission. And check your insurer's list: Cigna's policy accepts conditions like knee osteoarthritis, asthma, and PCOS that other standard lists omit.

Document prior weight management efforts with dates. Cigna's standard policy wants a 3-month behavioral modification and diet trial; Aetna's wants 6 months in a structured program. Even informal efforts count if they're in the chart with dates: a documented diet-and-exercise conversation, a dietitian referral, or program enrollment. Undated efforts are the ones reviewers discount.

Ask for a letter of medical necessity upfront. Don't wait for a denial. A letter explaining your clinical history and why this medication is specifically indicated for you gives the reviewer more to approve on than a bare PA form. Our LMN guide includes a copy-ready template your prescriber can adapt.

Know which drug your plan prefers. Some plans cover Zepbound but not Wegovy, or vice versa; CVS Caremark's template formularies currently prefer Wegovy. If you're flexible on which GLP-1 you receive, ask your prescriber to check formulary preference before submitting. Requesting the preferred drug from the start avoids a denial and re-submission.

Plan for renewal from day one. Aetna's and the FEP's standard policies require roughly 5% weight or BMI reduction to renew. Ask your prescriber to record your baseline weight and schedule a weigh-in before the authorization lapses, so the renewal packet writes itself.

Follow up proactively. Calling your insurer every 3–4 business days keeps your request from being forgotten and can surface outstanding information requests before they expire. In 2026, the deadlines are on your side: 7 calendar days for CMS-regulated plans and 15 days for employer plans, so a stalled request is something you can escalate, not just wait out.

---

Prior authorization is a process, not a verdict. In the most recent data, most denials were never challenged, while a large share of the challenges succeeded, particularly those backed by a strong letter of medical necessity and a peer-to-peer review. Talk with a licensed healthcare provider about whether Wegovy or Zepbound may be appropriate for you before starting any submission; these are prescription medications, and the clinical documentation only your prescriber can provide is what carries the request. If insurance isn't working for you at all, our GLP-1 without insurance guide covers cash-pay and compounded alternatives.